Table 1 Baseline characteristics of AF patients
| Â | 2013 n=691 | 2018 n=1066 | 2023 n=1068 | Total n=2825 | P-value |
|---|---|---|---|---|---|
Age, y | 70.93±11.19 | 72.44±11.44 | 72.10±12.15 |  | 0.026 |
Female, n(%) | 391(56.6%) | 548(51.4%) | 550(51.5%) | 1489(52.7%) | 0.063 |
Paroxysmal atrial fibrillation, n(%) | 105(15.2%) | 254(23.8%) | 166(15.5%) | 1404(49.7%) | 0.000 |
Non-valvular AF, n(%) | 579(83.8%) | 914(85.7%) | 945(88.5%) | 2438(86.3%) | 0.016 |
CHA2DAS2-VASc | 3.72±1.90 | 3.68±1.86 | 3.95±1.86 |  | 0.000 |
CHA2DAS2-VASc, n(%) (Male:≥2,Female:≥3), | 556(80.5%) | 854(80.1%) | 917(85.9%) | 2327(82.4%) | 0.001 |
HAS-BLED | 1.77±0.93 | 2.77±1.12 | 2.91±1.07 |  | 0.000 |
HAS-BLED≥3 | 136(19.7%) | 585(54.9%) | 695(65.1%) | 1416(50.1%) | 0.000 |
Comorbidities, n (%) | |||||
 Heart faliure | 422(61.1%) | 688(64.5%) | 686(64.2%) | 1796(63.6%) | 0.287 |
 Coronary atherosclerotic heart disease | 260(37.6%) | 488(45.8%) | 470(44.0%) | 1218(43.1%) | 0.003 |
 Hypertension | 421(60.9%) | 521(48.9%) | 602(56.4%) | 1544(54.7%) | 0.000 |
 Diabetes | 159(23.0%) | 259(24.3%) | 348(32.6%) | 766(27.1%) | 0.000 |
 Post-PCI | 26(3.8%) | 110(10.3%) | 150(14.0%) | 286(10.1%) | 0.000 |
 Previous stroke | 151(21.9%) | 131(12.3%) | 104(9.7%) | 386(13.7%) | 0.000 |
Antithrombotic strategies, n(%) | |||||
 Anticoagulation | 212(30.7%) | 569(53.4%) | 773(72.4%) | 1554(55.0%) | 0.000 |
 Antiplatelet therapy | 311(45.0%) | 53(5.0%) | 54(5.1%) | 418(14.8%) | |
 Anticoagulation combined with antiplatelet therapy | 11(1.6%) | 236(22.1%) | 132(12.4%) | 379(13.4%) | |
 Other | 15(2.2%) | 164(15.4%) | 8(0.7%) | 187(6.6%) | |
 No antithrombotic therapy | 142(20.5%) | 44(4.1%) | 101(9.5%) | 287(10.2%) | |
Low risk of stroke(Male:<2,Female:<3) | |||||
 Anticoagulation | 76(56.3%) | 131(61.8%) | 113(74.3%) | 320(64.1%) | 0.000 |
 Antiplatelet therapy | 26(19.3%) | 6(2.8%) | 10(6.6%) | 42(8.4%) | |
 Anticoagulation combined with antiplatelet therapy | 0(0.0%) | 32(15.1%) | 8(5.3%) | 40(8.0%) | |
 Other | 1(0.7%) | 28(13.2%) | 1(0.7%) | 30(6.0%) | |
 No antithrombotic therapy | 32(23.7%) | 15(7.1%) | 20(13.2%) | 67(13.4%) | |
High risk of stroke(Male:≥2,Female:≥3) | |||||
 Anticoagulation | 136(24.5%) | 438(51.3%) | 660(72.1%) | 1234(53.1%) | 0.000 |
 Antiplatelet therapy | 285(51.3%) | 47(5.5%) | 122(13.3%) | 454(19.5%) | |
 Anticoagulation combined with antiplatelet therapy | 11(2.0%) | 204(23.9%) | 46(5.0%) | 261(11.2%) | |
 Other | 14(2.5%) | 136(15.9%) | 7(0.8%) | 157(6.7%) | |
 No antithrombotic therapy | 110(19.8%) | 29(3.4%) | 81(8.8%) | 220(9.5%) | |
Use of OAC | |||||
 Warfarin: NOAC n%:n% | 32%:0.3% | 36.9%:38.6% | 7.4%:77.2% |  | 0.000 |